GLAUCOMA 360

Ora Chief Medical Officer Gustavo De Moraes, MD, PhD, MPH, speak with Ophthalmology Times®' Sheryl Stevenson to discuss some of the cutting-edge advancements in therapies and diagnostics for the treatment of glaucoma patients.

Glaucoma 360 is being held at the Grand Hyatt San Francisco at Union Square, and the meeting brings together celebration, innovation, and education in its efforts to eradicate glaucoma, with the Gala serving as the traditional kickoff of the event.

Glaucoma 360's co-founders and co-chairs Adrienne L. Graves, PhD, and Andrew G. Iwach, MD, speak with Ophthalmology Times®' Sheryl Stevenson on what attendees can expect from this year's annual meeting.

Region may have world’s highest rate, investigators say.

Investigators from various companies described their diagnostic offerings at the Glaucoma Research Foundation’s 2021 New Horizons Forum.

Telemedicine provides readiness in time of crisis.

Shan C. Lin, MD, co-research director, Glaucoma Center of San Francisco, speaks on the highlights from his presentation on the latest in the three forms of cyclophotocoagulation commonly used by clinicians.

J. Michael Jumper, MD, a retinal specialist at West Coast Retina (San Francisco, CA), discusses the highlights of his Glaucoma 360 presentation analyzing the impact and lasting effects of intraocular injections and retinal diseases in creating glaucoma as well as the evolving collaboration between retinal and glaucoma specialists.

L. Jay Katz, MD, of the Wills Eye Hospital, Philadelphia, PA, discusses the highlights of his Glaucoma 360 presentation on secondary glaucoma due to intravitreal steroids, and what ophthalmologists can do to minimize the risk of severe visual impairment in patients.

Tom Mitro, president, COO of Aerie Pharmaceuticals, discusses the key highlights from an industry panel discussion titled "Innovate without borders," held during the Glaucoma 360 New Horizons Forum, including the company's role in expanding into the global glaucoma therapeutics market.

Results of a survey among ophthalmologists indicate that patients are receiving fewer examinations — with worsening glaucoma, says S. Fabian Lerner, MD, speaking at the Glaucoma 360 New Horizons Forum.

A new therapy provides noninvasive nighttime IOP control by programming the desired pressure into the device, explained John Berdahl, MD, during the New Horizons Forum.

Glaukos Corporation's COO Chris Calcaterra gives an update on the company's latest 24-month phase 2b data for its iDose TR sustained-release travoprost implant, next steps for securing FDA approval, and his outlook for 2021.

Joseph F. Panarelli, MD, associate professor of ophthalmology, NYU Langone Medical Center, shares some clinical pearls for managing masquerade syndromes and determining when it is not glaucoma.

Donald L. Budenz, MD, MPH, shares the key takeaways from his Shaffer-Hetherington-Hoskins Lecture, focusing on glaucoma epidemiology, presented during the 2021 Glaucoma 360's 25th Annual Glaucoma Symposium CME.

The traditional treatment for primary angle-closure (PAC) and PAC glaucoma (PACG) is laser peripheral iridotomy (LPI) to facilitate aqueous outflow followed by medical treatment with drops to decrease the intraocular pressure (IOP).

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

Robert L. Stamper, MD, discusses the findings of a study analyzing the effects of corneal mechanics on IOP, presented during the virtual Glaucoma 360 meeting.

During the 2021 Glaucoma 360 meeting, Ruth D. Williams, MD, speaks on the highlights and key findings from the EAGLE study, which showed clear lens extraction surgery may be a better initial treatment for some glaucoma patients.

Andrew Iwach, MD, and Adrienne Graves, PhD, co-founders of Glaucoma 360, preview what attendees will experience at the 2021 version of the CME/CE Symposia, Annual Gala, and New Horizons Forum.

Amid a pandemic, the Glaucoma Research Foundation is holding its annual gala online, funding aspirations for a glaucoma-free world with a goal of raising $1 million.

Pharmaceutical representatives share what keeps them up at night within the ophthalmic space.

In this fourth installment on "2020 vision," pharmaceutical representatives share their outlook on what lies ahead for glaucoma innovations within the ophthalmic space.

How gonioscopy can offer ophthalmologists an option in treating patients with glaucoma

Researchers must weigh emotional, financial, and reputational considerations

Trabeculectomy may offer better results with more severe glaucoma

Technology is off to a good start, but improvements still needed

Diagnostic and monitoring advances in glaucoma need fine-tuning

With an eye on innovation, money is driving research of new therapies and devices.

Industry develops creative approaches to help increase patient medication adherence